Integra LifeSciences (NASDAQ:IART) Issues FY25 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its FY25 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $2.41 to $2.51 for the period, compared to the consensus estimate of $2.53. The company issued revenue guidance of $1.650 billion to $1.715 billion, compared to the consensus revenue estimate of $1.71 billion. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Wall Street Analyst Weigh In

IART has been the topic of several research reports. Citigroup increased their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. Morgan Stanley assumed coverage on Integra LifeSciences in a report on Monday, December 2nd. They set an “underweight” rating and a $20.00 target price on the stock. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Stock Down 2.3 %

Shares of Integra LifeSciences stock traded down $0.58 during trading on Wednesday, reaching $24.14. The company had a trading volume of 209,393 shares, compared to its average volume of 589,260. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $44.69. The firm’s fifty day moving average is $23.71 and its 200-day moving average is $21.83. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -268.19, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $442.65 million for the quarter, compared to analysts’ expectations of $445.15 million. During the same period in the prior year, the company earned $0.89 earnings per share. The firm’s revenue was up 11.5% compared to the same quarter last year. On average, analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. The trade was a 2.94 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.10% of the stock is currently owned by insiders.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.